Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in moderate to severe chronic plaque psoriasis
NCT02905006Phase 2Completed
- Sponsor
- UCB
- Start
- Aug 2016
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of bimekizumab in psoriasis (6 arms), sponsored by UCB. Primary endpoint: Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at 12 weeks. Started Aug 2016; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02905006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905006.